Future of Clinical Computer Systems: Panel

At Montrium’s Clinical QAI Day, Frank Henrichmann joined a key panel on the future of clinical computer systems – from rising quality and compliance demands to AI-enabled solutions that not only document processes but improve them.

QFINITY took part in a key panel discussion at Montrium’s Clinical QAI Day. The panel discussion focused on the future of clinical computer systems.

The demands for quality and compliance in clinical environments continue to rise. At the same time, the need for efficient, intelligent solutions is growing – systems that not only document processes but actively improve them. As a result, modern AI-enabled technologies will play an increasingly significant role.

The specialist event brought together leading experts from Quality Management, Clinical Operations, and Digitalization to present and discuss current developments in clinical technologies and regulations.
Frank Henrichmann of QFINITY contributed to core panel discussions in which experts shared their perspectives on the future of clinical computer systems.

QFINITY used the event to actively shape these developments, provide professional insights, and explore potential avenues for collaboration.

Intelligent systems should not just document processes but improve them – without sacrificing quality or compliance.

Building Quality In – Real-World QbD Implementation Stories

“Quality by Design” (QbD) is far more than a theoretical framework – it is a working and thinking approach that aligns clinical studies with quality from the very beginning.
In this panel, Frank Henrichmann and other experts discussed how organizations can integrate QbD into their clinical processes in practice.

The focus was on real implementation experiences:

How can cross-functional alignment between teams be achieved?
What process adjustments and workflow redesigns are required?
What challenges arise during implementation – and how can they be overcome?
What measurable improvements result for compliance, efficiency, and study quality?

The practical insights made one thing clear: QbD is not a one-time project but a continuous, collaborative approach that makes clinical studies smarter, more robust, and more resilient from a regulatory perspective.

AI Compliance Playbook – Navigating EMA and FDA Draft Guidances

Artificial intelligence is increasingly finding its way into clinical research – and with it, regulatory expectations continue to grow.
In another panel, Frank Henrichmann discussed the latest draft guidances and position papers from EMA and FDA on the use of AI in clinical studies.

The discussion explored, among other topics:

Requirements for risk-based credibility assessments of AI tools
Expectations regarding transparency, governance, and lifecycle management
Practical control mechanisms that organizations can already implement today

The session highlighted that responsible and compliant use of AI requires clear structures, continuous oversight, and a deep understanding of regulatory boundaries – while also demanding the courage to safely bring innovative solutions into practice.

A step into the future of quality management

QFINITY will continue to support and drive these developments – through active exchange, expertise, and participation in key industry dialogues.

You can find additional updates from QFINITY here. Feel free to visit QFINITY’s LinkedIn channel to stay informed.